a 2023

Transarterial chemoembolization of hepatocellular carcinoma in patients with the most common comorbidities or previous oncologic malignancy in remission.

STRAKA, Matej, Tomáš ANDRAŠINA, Jakub HUSTÝ, Peter MATKULČÍK, Tomáš KAZDA et. al.

Basic information

Original name

Transarterial chemoembolization of hepatocellular carcinoma in patients with the most common comorbidities or previous oncologic malignancy in remission.

Name in Czech

Transarteriální chemoembolizace hepatocelulárního karcinomu u pacientů s nejčastějšími komorbiditami nebo předchozí onkologickou malignitou v celkové remisi.

Authors

Edition

CIRSE 2023, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30224 Radiology, nuclear medicine and medical imaging

Country of publisher

Denmark

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

Keywords in English

Transarterial chemoembolization; hepatocellular carcinoma; comorbidities; remission

Tags

International impact
Změněno: 5/4/2024 10:08, Mgr. Tereza Miškechová

Abstract

V originále

Purpose: To analyze whether previously diagnosed common comorbidity (diabetes mellitus, myocardial infarction, ischemic stroke, chronic obstructive pulmonary disease (COPD) or prior malignancy in complete remission (CR) are independent risk factors afecting survival of patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation (TACE). Conclusion: Patiens with HCC treated with TACE and a history of mentioned comorbidities or other malignant tumor in complete remission have non-inferior survival compared to patients without comorbidities.

Links

MUNI/A/1222/2022, interní kód MU
Name: Vyhodnocení účinnosti a optimalizace protokolů radiologických zobrazovacích a intervenčních metod
Investor: Masaryk University, Evaluation of Efficacy and Optimization of Radiological Imaging and Interventional Methods